The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe.
The alfapump® is a fully-implantable, wirelessly-charged, CE-marked system that automatically and continuously pumps ascites from the abdominal cavity into the bladder, where the body eliminates the ascites naturally.
The alfapump® system’s DirectLink Technology allows physicians to monitor pump performance and more effectively manage their patients.
Since 2018, the alfapump® has been included in the EASL (European Association for the Study of the Liver) clinical practice guidelines.
The ascites is removed from the body on a continual basis, thereby preventing fluid build-up in the abdomen.
The alfapump® is programmed by the patient’s doctor allow an optimal removal of ascites on a daily basis, customised to the patient’s needs.
The alfapump® has a special mechanism which ensures ascites is only moved into the bladder if there is space and it will turn itself off if there is no ascites in the abdominal cavity, ensuring optimal fluid management with no inconvenience for the patient.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.